[Combination of antimetabolites and alkylating agents in the treatment of advanced breast cancer].
An association of 5-fluoruracyl (or methotrexate) and cyclophosphamide was used in the treatment of 20 cases of hormone-resistant breast cancer. Five objective regressions were obtained. Mean survival here was 28.25 (S.D. 2.87) months, as opposed to 12.75 (S.D. 6.93) months in the remainder. Side-effects of various kinds were noted in 9 patients.
D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000627:therapeutic use*; D000963:Antimetabolites / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D013997:Time Factors
D000477:Alkylating Agents; D000963:Antimetabolites; D003520:Cyclophosphamide; D005472:Fluorouracil
L'associazione di antimetaboliti ed alchilanti nel trattamento del cancro mammario in fase avanzata